Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 3
1990 3
1991 3
1993 4
1994 3
1995 2
1997 4
1998 1
2000 1
2001 1
2002 1
2005 1
2008 2
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
Du Plessis DJ. Du Plessis DJ. Urology. 1991;37(2 Suppl):20-4. doi: 10.1016/0090-4295(91)80097-q. Urology. 1991. PMID: 1992599 Review.
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), significantly reduced bone pain, and fewer patients experienced worsening pain than in the control group. ...Nilutamide was generally well t …
In a short-term (29 days) comparison of nilutamide plus buserelin and buserelin plus placebo, nilutamide (300 mg/day), signifi …
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, Chowdhury S, Frydenberg M, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter D, Yip S, Zhang AY, Zielinski RR, Davis ID; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Sweeney CJ, et al. Lancet Oncol. 2023 Apr;24(4):323-334. doi: 10.1016/S1470-2045(23)00063-3. Lancet Oncol. 2023. PMID: 36990608 Clinical Trial.
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 …
Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurre …
Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis.
Rashid M, Shamshavali K, Chhabra M. Rashid M, et al. Curr Clin Pharmacol. 2019;14(2):108-115. doi: 10.2174/1574884714666190112151202. Curr Clin Pharmacol. 2019. PMID: 30648519 Free PMC article.
In addition, patients on Nilutamide showed prolonged progression-free survival and overall survival. Nausea and vomiting were the most common adverse events reported in Nilutamide group. CONCLUSION: Evidence suggests that patients with mPCa who underwent orchiectomy …
In addition, patients on Nilutamide showed prolonged progression-free survival and overall survival. Nausea and vomiting were the mos …
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al. Janknegt RA, et al. J Urol. 1993 Jan;149(1):77-82; discussion 83. doi: 10.1016/s0022-5347(17)36003-2. J Urol. 1993. PMID: 7678043 Clinical Trial.
Progression-free survival was significantly longer in the nilutamide group (median time to progression 20.8 months on nilutamide and 14.9 months on placebo, p = 0.005). Median time to death from prostatic cancer was 30.0 months in the placebo group and 37 months in …
Progression-free survival was significantly longer in the nilutamide group (median time to progression 20.8 months on nilutamide
A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Béland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewari HD. Béland G, et al. Cancer. 1990 Sep 1;66(5 Suppl):1074-9. doi: 10.1002/cncr.1990.66.s5.1074. Cancer. 1990. PMID: 2203517 Clinical Trial.
Progression-free survival was improved initially in the nilutamide group, but the median time to progression was 12 months for both groups. Despite an increase in the median length of survival from 18.9 to 24.3 months with the nilutamide, the survival time was not s …
Progression-free survival was improved initially in the nilutamide group, but the median time to progression was 12 months for both g …
Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group.
Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FM. Dijkman GA, et al. J Urol. 1997 Jul;158(1):160-3. doi: 10.1097/00005392-199707000-00051. J Urol. 1997. PMID: 9186345 Clinical Trial.
MATERIALS AND METHODS: A large double-blind trial was done on 457 patients randomized to receive nilutamide or placebo after orchiectomy. RESULTS: At 8.5 years of followup significant benefits were found for progression and survival in favor of patients receiving niluta
MATERIALS AND METHODS: A large double-blind trial was done on 457 patients randomized to receive nilutamide or placebo after orchiect …
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.
Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM. Madan RA, et al. Clin Cancer Res. 2008 Jul 15;14(14):4526-31. doi: 10.1158/1078-0432.CCR-07-5048. Clin Cancer Res. 2008. PMID: 18628467 Free PMC article. Clinical Trial.
PURPOSE: We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. The study employed vaccine, the hormone nilutamide, and the combined therapy (crossover for each arm) with an endpoint of time to prog …
PURPOSE: We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. T …
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R, et al. Kuhn JM, et al. N Engl J Med. 1989 Aug 17;321(7):413-8. doi: 10.1056/NEJM198908173210701. N Engl J Med. 1989. PMID: 2503723 Clinical Trial.
Gonadotropin-releasing hormone (GnRH) analogues administered for the treatment of advanced prostatic cancer induce a transient increase in plasma testosterone levels during the first week of treatment, often with a secondary rise in plasma levels of prostatic acid phosphatase and …
Gonadotropin-releasing hormone (GnRH) analogues administered for the treatment of advanced prostatic cancer induce a transient increase in p …
French multicentre trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report.
Chatelain C, Rousseau V, Cosaert J. Chatelain C, et al. Eur Urol. 1994;26 Suppl 1:10-4. doi: 10.1159/000475425. Eur Urol. 1994. PMID: 7737255 Clinical Trial.
This trial compares Casodex (ICI 176,334) monotherapy with the combination of castration (medical or surgical) plus nilutamide. The trial is now closed to entry, 270 patients having been recruited from 32 French centres. ...
This trial compares Casodex (ICI 176,334) monotherapy with the combination of castration (medical or surgical) plus nilutamide. The t …
33 results